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Expression of programmed death-ligand 1 (PD-L1) in cancer cells plays an important role in 
cancer-immune cell interaction. The emerging evidence suggests regulation of PD-L1 
expression by several tumor microenvironmental cues. However, the association of PD-L1 
expression with chemical and mechanical features of the tumor microenvironment, 
specifically epidermal growth factor receptor (EGFR) signaling and matrix stiffness, remains 
elusive. Herein, we determine whether EGFR targeting and substrate stiffness affect the 
regulation of PD-L1 expression. Breast carcinoma cell lines, MCF7 and MDA-MB-231, were 
cultured under different conditions targeting EGFR and exposing cells to distinct substrate 
stiffness to evaluate PD-L1 expression. Furthermore, the ability to form aggregates in short-
term culture of breast carcinoma cells and its effect on expression level of PD-L1 was probed. 
Our results indicated that PD-L1 expression was altered in response to both EGFR inhibition 
and substrate stiffness. Additionally, a positive association between the formation of 
multicellular aggregates and PD-L1 expression was observed. MDA-MB-231 cells expressed 
the highest PD-L1 level on a stiff substrate, while inhibition of EGFR reduced expression of 
PD-L1. The results suggested that both physical and chemical features of tumor 
microenvironment regulate PD-L1 expression through alteration of tumor aggregate 
formation potential. In line with these results, the in-silico study highlighted a positive 
correlation between PD-L1 expression, EGFR signaling, epithelial to mesenchymal transition 
related transcription factors (EMT-TFs) and stemness markers in metastatic breast cancer. 
These findings improve our understanding of regulation of PD-L1 expression by tumor 
microenvironment leading to evasion of tumor cells from the immune system. 














It is broadly understood that the tumor microenvironment (TME) and its interplay with 
cancer cells play a crucial role in tumor initiation, progression, metastasis, and drug response 
[1, 2]. A large number of studies highlighted the importance of non-cellular features of TME 
including extracellular matrix (ECM) and its stiffness in the induction of metastasis and drug 
resistance in various solid tumors [3-6]. The physical and chemical characteristics of TME 
can control the behavior and function of cancer cells [1, 7, 8]. Mechanical characteristics of 
TME changes during cancer progression expose tumor cells to different mechanical signals 
[9]. Variation of TME stiffness induced by cellular and non-cellular components is 
recognized as a pro-tumorigenic factor [10-12]. Activation of various oncogenic signaling 
pathways through the cellular and physical properties of TME has been reported previously, 
resulting in enhancing hypoxia, invasiveness, stemness and immune-escaping capability of 
cancer cells [13, 14].  
During the past decade, immunotherapy has witnessed a revolution in cancer therapy with the 
development of immune checkpoint inhibitors, monoclonal antibodies against cytotoxic T 
lymphocyte antigen 4 (CTLA-4) and programmed cell death protein-1 (PD-1) or their 
ligands, including PD-1 ligand 1 (PD-L1) [15]. Emerging evidence highlighted roles of TME 
and ECM remodeling in regulating the cancer-immunity cycle [15-17]. However, the 
contribution of the ECM remodeling in shaping the immune microenvironment of the tumor 
is only beginning to be studied. Mechanical features of TME are increasingly recognized as 
crucial factors in immune cell trafficking, activation and immunological synapse formation 
[18]. The density of ECM and basement membrane composition are regulated by stromal 
matrix components and plays a crucial role in immune cell migration, spatial distribution, and 
activation of immune-escaping features of cancer cells [15, 17, 19]. Additionally, numerous 












suppression capability of TME and immune-escaping potential of cancer cells. Recently 
several studies highlighted immune-modulatory effects and positive association of activation 
of epidermal growth factor receptor (EGFR) signaling with PD-L1 expression in TME [20, 
21]. However, the association between matrix stiffness and EGFR on the expression of PD-
L1 has not been elucidated.  
There is a growing interest in the three-dimensional culture of cancer cells through the 
formation of 3D multicellular aggregates. Cellular aggregates display a variety of features 
which could better mimic the tumor microenvironment [22, 23]. An increasing number of 
studies demonstrated that the formation of tumor spheroids and cell aggregates could 
modulate numerous signaling pathways including stemness-related pathways [24-26]. 
Despite these studies, it is not yet been established whether the formation of cell aggregates 
can regulate the PD-L1 expression. This study was designed to determine whether the 
chemical and mechanical features of TME regulate the multicellular cancer aggregate (MCA) 
formation ability and PD-L1 expression in human breast cancer cells. Our findings postulated 
regulation of PD-L1 expression by EGFR signaling pathway, substrate stiffness, and MCA 
formation.  
2. Materials and Meth ds 
2.1 Cell culture 
Cells of human breast cancer cell lines MCF7 (non-invasive) and MDA-MB-231 (highly 
invasive) were acquired from the University of Technology Sydney (UTS), Faculty of 
Science. The cells were maintained in the RPMI culture medium (ThermoFisher Scientific, 
USA) containing 10% fetal bovine serum (FBS) (ThermoFisher Scientific, USA) and 
supplemented with 1% L-glutamate (Thermo Fisher Scientific, USA) in an atmosphere of 5% 












illustrated in figure 1, two as chemical groups and three as mechanical groups that referred to 
as non-treated, Cetuximab treated, stiff, semi-soft and soft substrates, respectively. Figure 1 
presents a schematic illustration of workflow that will be described below. 
2.2 Substrate preparation and characterization 
To examine the effect of substrate stiffness on PD-L1 expression and the MCA formation 
ability of cancer cells, polydimethylsiloxane (PDMS) substrates with different stiffness were 
utilized. These substrates were prepared by mixing the silicone elastomer with the curing 
agent (Sylgard 184, Dow Corning, USA). Varying the ratio of elastomer to the curing agent 
allowed us to achieve PDMS substrates with different elastic modulus with negligible 
changes in other chemical and physical properties [27, 28]. Here we fabricated PDMS 
substrates by mixing silicone elastomer with the curing agent at a ratio of 10:1 and 50:1 and 
75:1, to obtain stiff, semi-soft and soft substrates, respectively. Then, the mixture was 
degassed to expel bubbles and cured for 24 hours at 70°C. To ensure cell-substrate adhesion, 
synthesized substrates were treated via air plasma by a low-frequency plasma generator (230 
V, Harrick Plasma, USA) at 30 W for 3 minutes, sterilized by UV for 30 minutes followed by 
coating with a thin layer of fibronectin (10μg/ml, Sigma-Aldrich, USA). Finally, the 
substrates were rinsed with PBS to remove excess protein and were immediately employed 
for cell seeding.  
The substrate elasticity was measured by atomic force microscopy (AFM) indentation 
technique using a Nanowizard II atomic force microscope (JPK Instruments, Germany). The 
indentation was performed with V-shaped silicon nitride cantilever with a spring constant of 
0.046 N/m (HYDRA6V-200NG, APPNANO, USA), at an approach velocity of 3 μm/s and a 
maximum indentation depth of 0.5 μm.  For each substrate, three samples were prepared, and 












moduli were calculated from at least 150-200 curves for each substrate (from three 
independent experiments) and reported as mean±SD. Briefly, in this technique, a flexible 
cantilever with a sharp tip indented the surface. During the indentation, the substrate-
cantilever interaction led to a vertical deflection of the cantilever that was converted to the 
force and recorded against the indentation. The resulting force-indentation curve was used to 
obtain Young’s modulus according to the modified Hertz model for a quadrilateral pyramid 





𝛿2    (1) 
where, F is the force, δ is the indentation depth, and α is the half angle of pyramid tip which 
was set to 17.5°. The Poisson’s ratio of substrates (νsub) was assumed to be 0.5 considering an 
incompressible material property for PDMS.  
2.3 Anti-EGFR treatment 
To assess the potential correlation between the PD-L1 protein expression with EGFR 
signaling and the MCA formation ability, the EGFR pathway was targeted by the anti-EGFR 
antibody Cetuximab (Merk, Germany). Cetuximab blocked EGFR through its binding to the 
extracellular domain of EGFR  preventing receptor dimerization [30]. For immunostaining 
and ELISA, breast cancer cells were exposed to a culture medium supplemented with 
10µg/ml Cetuximab for 48 hours. For MCA formation experiments, breast cancer cells were 
treated with the mentioned concentration of Cetuximab during the MCA formation process. 













2.4 Evaluation of the PD-L1 expression 
The PD-L1 expression of breast cancer cell lines was analyzed among different chemical and 
mechanical groups by immunofluorescence staining and enzyme-linked immunosorbent 
assay (ELISA). PD-L1 assessment was performed before and after formation of cellular 
aggregates. 
2.4.1 Immunofluorescence staining of PD-L1 
For PD-L1 immunostaining experiments, PDMS was spin-coated onto the glass slides at 
2000 rpm for 30 seconds. Two types of breast cancer cells were cultured among five study 
groups. After 24 hours, the cells were fixed and permeabilized for 10 min with chilled 100% 
methanol (SigmaAldrich, USA). The fixation was followed by three times washing with 
phosphate-buffer saline (PBS) solution (ThermoFisher Scientific, USA) and blocking with 
1% bovine serum albumin (BSA) (ThermoFisher Scientific, USA) in PBS for 60 min. Then, 
the cells were incubated with a rabbit monoclonal anti-PD-L1 antibody (dilution 1:100, 
ab209960, Abcam, USA) in PBS containing 1% BSA for overnight at 4ºC. Finally, the 
samples were washed and further incubated with 4,6-diamino-2-phenylindole (DAPI) 
(dilution 1:1000, D9542; SigmaAldrich, USA) for 5 min at room temperature. An inverted 
fluorescence microscope (Olympus IX71, USA) was utilized to capture the 
immunofluorescence images.  
2.4.2 Measuring PD-L1 concentration using ELISA 
The PD-L1 concentration was assessed among chemically and mechanically treated groups of 
the two breast carcinoma cell lines using quantitative ELISA kit (ab214565, Abcam, USA). 
ELISA was performed according to the manufacturer’s instruction. First, cells were seeded at 
the concentration of 10
5












cultured in non-treated and Cetuximab-treated groups. After 48 hours, the samples were 
extracted from the adherent cells and prepared according to the manufacturer’s protocol. 
Briefly, the samples were added to the appropriate wells and incubated with the capture and 
detector antibodies for 1 hour at room temperature, then washed with the washing buffer 
followed by incubation with 3,3’,5,5’-Tetramethylbenzidine (TMB) development solution 
and the stop solution. Finally, the optical density (OD) was recorded at 450 nm immediately 
after adding the stop solution. Eight standard samples with the pre-determined PD-L1 
concentration were used to obtain a standard curve (data not shown). The standard curve was 
created by plotting the absorbance value for each standard concentration against the target 
protein concentration. This curve was fitted and employed to determine the concentration of 
PD-L1 protein in the samples. For each sample, three independent measurements were 
performed, and all the measurements were conducted in duplicate for statistical analysis.  
2.5 MCA formation 
2.5.1 Pre-treatment of the microwells before cell seeding 
MCAs were formed using the microwell technique [23, 32, 33]. The 3D SpheroFilm™ 
microwell was obtained from Incyto Co. (Korea) with the inner diameter of 300 μm and the 
well depth of 300 μm. Each device consisted of 361 silicone elastomer microwells. To 
prepare the microwells for cell culturing, their surface was UV sterilized and pretreated with 
100% ethanol (SigmaAldrich, USA) repeatedly pipetted to remove the air bubbles from the 
wells. Then the wells were washed three times with PBS by repeatedly pipetting and 












2.5.2 Cell seeding in the microwells 
For each cell line, five SpheroFilm devices were used, two devices for non-treated and 
Cetuximab-treated cells and three devices for stiff, semi-soft and soft groups. First, breast 
cancer cells were cultured on the three mentioned PDMS substrates for 24 hours before 
introducing into the microwells. After removing the medium from the SpheroFilm devices, a 
total number of 1.4×10
6
 breast cancer cells were distributed over the microwell surfaces of 
each group at the concentration of 2×10
5
 cells/ml. After 15 minutes of cell seeding, the 
suspending cells were removed by aspiration, and fresh growth media was added. The 
medium was changed every day until the end of the MCA formation assay. For Cetuximab-
treated group, the cells were exposed to the medium containing Cetuximab at the 
concentration of 10 μg/ml. 
2.5.3 Isolation of the MCA from the microwells 
 After two days of culturing in the microwells, multicellular breast cancer aggregates were 
dislodged by pipetting growth medium onto the microwells, repeatedly. MCAs with the size 
of above 100 μm were obtained using a cell strainer with a pore size of 100 μm. After adding 
the MCAs, the strainer was flipped, and the growth medium was added to the bottom surface 
of strainer to collect the MCAs. The isolated MCAs were transferred to the appropriate wells 
or slides for further assessments. 
2.6 MCA characterization 
To evaluate the MCA formation ability of breast cancer cells with the different expression of 
PD-L1, the MCAs were characterized by performing live and dead assay, counting the 













2.6.1 Cell viability of MCA 
MCAs were labeled directly in 48-well plates using a Cellstain double staining kit (Sigma 
Aldrich, USA) according to the manufacturer’s protocol. The viable cells were labeled with 
Calcein-AM which stained the cytoplasm in green. Nuclei of the dead cells were labeled with 
propidium iodide in red. The MCAs were incubated in the assay solution (5 mL of PBS 
containing 10 μL of calcein-AM and 5 μL of propidium iodide) in each well for 15 minutes at 
37˚C.  The live/dead fluorescence images were captured using an inverted fluorescence 
microscope (Olympus IX71, USA). 
2.6.2 Measurement of MCAs number and diameter 
The formed MCAs among different groups were imaged using an Olympus IX71 inverted 
microscope. The total number of MCAs was determined by adding 400 μl of the final MCA 
suspension (4ml) in 48-well plate. The average diameter of MCAs was also calculated by 
measuring the diameter of at least 40 MCAs in each group. ImageJ (NIH, Bethesda, MD) was 
employed for number and diameter measurements [35]. Most of the MCAs presented a 
spherical shape. For those had ellipsoid shape, the longest dimension was measured as the 
diameter. 
2.6.3 Immunofluorescence staining of PD-L1 
To assess the PD-L1 expression in MCAs, isolated MCAs were stained with anti-PD-L1 
antibody. First, the MCAs were fixed with chilled 100% methanol for 10 min at -20 ºC, then 
centrifuged at a speed of 1200 rpm for 5 min to remove methanol. The samples were washed 
with PBS followed by blocking with 1% BSA for 1 hour at room temperature. Then the 
MCAs were stained with a rabbit monoclonal PD-L1 antibody by overnight incubation at 












Finally, the nuclei were stained with DAPI for 5 minutes and the images captured using an 
inverted fluorescent microscope. 
2.7 MCAs spreading 
Isolated MCAs were transferred to the 24-well plate and allowed to spread. The MCAs were 
monitored under a microscope to observe whether they attached to the surface. After the 
attachment of MCAs, the culture media was removed, and the fresh media added for the 
further cell aggregates cultivation and analysis. The PD-L1 expression of breast cancer cells 
in the spread MCAs was analyzed using the immunofluorescence staining of PD-L1 followed 
with measuring PD-L1 concentration by ELISA as described before.  
To measure the PD-L1 concentration after formation of MCAs, first, MCAs were attached 
and spread for 24 hours, then spread MCAs were dissociated using trypsin (SigmaAldrich, 
USA) and the number of cells counted among five study groups of MCF7 and MDA-MB-231 
spread aggregates. Finally, the counted cells were transferred to a new well at the 
concentration of 10
5
 cells/ml and incubated for another 24 hours. ELISA was performed 
according to the manufacturer’s instruction, as mentioned before. 
2.8 The TCGA data analysis 
The genomic alterations, co-expression, and correlation studies were performed on data from 
The Cancer Genome Atlas (TCGA), PanCancer Atlas Breast cancer database using 
TCGAWorkflow package under R-Software (version 3.8) and cBioportal 
(www.cbioportal.org). The protein-protein interaction analysis was performed by STRING 













The results of quantitative experiments were expressed as mean±SD. The statistical analysis 
was performed with Student t-test. 
*
p-value<0.05 was considered as a statistically significant 
and 
**
p-value<0.005 was considered as an extremely significant. Microscopic images are 
representative images from three independent experiments. All Immunofluorescence staining 
experiments were repeated three times and three to five different sections were captured by 
fluorescent microscope for each sample. Data shown for the MCA diameter are the averages 
from at least 40 number of MCAs from three independent experiments. PD-L1 ELISA was 
conducted in three separate replicates as mentioned before.  
3. Results 
3.1 PDMS substrates elastic modulus 
Three PDMS substrates with the different elastic moduli were achieved by controlling the 
ratio of polymer to the crosslinking agent. The elastic moduli of PDMS substrates with the 
ratio of 10:1, 50:1 and 75:1, were measured as 1.22±0.2 MPa, 32.38±2.2 kPa, and 5.10±0.4 
kPa, respectively. These values cover the physiologically relevant elastic moduli of TME that 
are used to examine how the substrate rigidity affects the biological behavior of cancer cells 
[36, 37]. As mentioned, these substrates are referred to as stiff, semi-soft and soft in this 
paper.  
3.2 Expression of PD-L1 protein in breast cancer cells  
First, we determined the expression of PD-L1 protein in two breast cancer cell lines among 
five groups of non-treated, CTX-treated, stiff, semi-soft, and soft. Figure 2 exhibits the 
immunofluorescent images of PD-L1 and nucleus of breast cancer cells, which demonstrates 












cancer cells. Consistent with the findings in the previous literature [38], high expression of 
PD-L1 protein was observed in MDA-MB-231 cells (figure 2B) whereas, there was a low 
expression of PD-L1 protein in MCF7 cells (figure 2A). To calculate the percentage of 
MDA-MB-231 cells with positive expression of PD-L1, the number of cells with positive 
PD-L1 fluorescent signal was counted and compared to the total number of cells in each 
figure using ImageJ (NIH, Bethesda, MD) [35]. The final values were calculated by 
averaging between three independent experiments for each study group. Application of anti-
EGFR antibody for 24 hours significantly reduced the PD-L1 protein level in MDA-MB-231 
cells from 92%±3% positive cells to 35%±6%, which revealed that the PD-L1 expression is 
positively related with the EGFR signaling. In addition, the effect of substrate stiffness on the 
PD-L1 expression was examined. The PD-L1 expression of MDA-MB-231 cells was affected 
not only by the chemical treatment but also by the substrate stiffness. Cancer cells on the stiff 
substrate expressed the most PD-L1 among three PDMS substrates with different rigidity. 
Substrate softening reduced the number of PD-L1 positive MDA-MB-231 cells from 
74%±5% for the stiff substrate to 50%±6%, and 22%±3% for the semi-soft and soft 
substrates, respectively. 
3.3 Characterization of the breast tumor MCAs 
In this paper, MCA formation was performed in microwells. We screened the MCA 
formation ability of two breast cancer cells in five study groups. For all groups, the single cell 
suspension was seeded into the microwells, and most of the cellular aggregates reached above 
100 µm after two days. The SpheroFilm device and MCA formation steps of two breast 
cancer cells are schematically illustrated in figure 3. Initially, cells settled in the bottom of 
microwells. After one day, the cells started to attach together and form cell aggregates. Later, 












Initially, we examined the cell viability of MCAs and confirmed that both cell lines displayed 
more than 95% viability by Calcein AM staining (figure 4A) in all groups of study. Due to 
the small size of MCAs (less than 300 µm), the necrotic core was not observed in any of 
them. Next, we examined whether the EGFR targeting and substrate stiffening involved in 
the MCAs formation. The total number of formed MCAs and their average diameter are 
shown in figure 4 (B and C). We observed a considerable difference in the number and 
diameter across the formed aggregates. Although both breast cancer cells successfully formed 
MCAs, MDA-MB-231 cells were able to form more MCA with a larger size. The total 
number of formed aggregates in different groups of breast cancer cells has been displayed in 
figure 4, while table 1 reports the number of single cells versus aggregates to establish an 
MCA titer. This titer was calculated by dividing the number of formed aggregates by the 
number of single cells added to the SpheroFilm device. Our results revealed that Cetuximab 
treatment resulted in the alteration of MCA formation ability of breast cancer cells. The 
treated cells decreased MCA formation ability in terms of number and diameter which 
suggests that MCA formation of cancer cells strongly depends on the EGFR activity 
(
*
p<0.005). MCA titer decreased from 1/5384 and 1/5000 for MCF7 and MDA-MB-231 cells 
in control groups to 1/7000 and 1/10000 in Cetuximab-treated groups, respectively.  
Table 1. Aggregate formation ability of breast cancer cells in different chemical and 
mechanical groups. Values display MCA titer which is the number of formed MCAs per 
number of single cells 
                Cell 
Group 
MCF7 MDA-MB-231 
Non-treated 1/5384 1/5000 
Treated 1/7000 1/10000 
Stiff 1/6086 1/4000 
Semi-soft 1/5833 1/6666 













Furthermore, the MCA formation ability of both cancer cells was altered with the substrate 
stiffening. MCF7 and MDA-MB-231 cells cultured on the stiff substrates revealed more 
ability for MCA formation compared with the softer substrates (
*
p<0.05). Although both cell 
lines respond to the substrate stiffness, non-invasive MCF7 cells showed more sensitivity 
than invasive MDA-MB-231 cells. The MCA titer of 1/6086 and 1/4000 in the stiff groups of 
MCF7 and MDA-MB-231 cells decreased to 1/14000 and 1/7368 in the soft groups, 
respectively. These changes were accompanied by a decrease in the average diameter of 
MCF7 MCAs from 200±43 µm to 167±54 µm by substrate softening (
*
p<0.05).  
Next, we examined whether PD-L1 is involved in the MCA formation induced by the EGFR 
blocking and substrate stiffening. Figure 5 provides representative immunofluorescent images 
of cancer aggregates, which reveals that MCA formation increased PD-L1 expression of 
breast cancer cells in the EGFR-dependent and stiffness-dependent manner. Breast MCAs 
from both cell lines characterized with the lower expression of PD-L1 in the soft group 
compared with the stiff group as well as the Cetuximab-treated group compared with the non-
treated group. These results suggest an upregulation of PD-L1 through the formation of 
MCA, which is mediated by chemical and mechanical factors.  
3.4 Assessment of the PD-L1 expression in spread breast MCA 
Next, we further investigated whether MCA formation affects PD-L1 expression. Since 
MCAs are the 3D structures of hundreds of cells, their PD-L1 immunostaining would not be 
adequate to confirm the induction of PD-L1 expression by MCA formation. Therefore, we 
examined the PD-L1 expression of MCAs after spreading for 24 hours to permit the 
formation of a cell monolayer. Figure 6A, and B illustrate the spreading of cellular aggregates 
and formation of the monolayer, which consisted of those cancer cells that were successfully 












intensity (MFI) of MCF7 and MDA-MB-231 cells was analyzed using ImageJ from at least 
three independent imaging experiments for each group of study and has been reported in 
figure 6C. MCF7 cells showed an increased PD-L1 expression not only in the MCAs but also 
in the spread aggregates, which demonstrates induction of the PD-L1 expression by the MCA 
formation. Quantification of fluorescent intensity in figure 6C revealed a positive correlation 
between the substrate stiffness and the PD-L1 expression of MCF7 cells (*p<0.05). As shown 
before, the spread MCAs of MDA-MB-231 cells showed that the expression of PD-L1 is 
closely related to the EGFR activity. Moreover, the PD-L1 staining of MDA-MB-231 cells in 
figure 6 indicates the PD-L1 expression in the stiff substrate is more than the soft substrate 
but not the semi-soft substrate. This result is consistent with the concentration of PD-L1 from 
ELISA in figure 7B which confirms that PD-L1 concentrations in the stiff and semi-soft 
groups of MDA-MB-231 cells are very close to each other. Moreover, ELISA before MCA 
formation (figure 7A) demonstrated similar results for the stiff and semi-soft groups of 
MDA-MB-231 cells. These findings suggest that although MDA-MB-231 cells exhibited a 
substrate-dependent expression of PD-L1, they are more sensitive to the substrate stiffness in 
the range of 5 to 35 KPa which are related to semi-soft and soft substrates in this study.  
To confirm the results of PD-L1 staining in figure 2, ELISA was employed to measure the 
PD-L1 concentration. In agreement with the PD-L1 staining results before multicellular 
formation, the PD-L1 concentration of MCF7 cells was measured below 30 pg/ml for all 
study groups (figure 7A). The PD-L1 protein concentration of invasive breast cancer cells 
(MDA-MB-231) was significantly reduced from 1898±62 pg/ml in the non-treated group 
to1341.6±110 pg/ml after EGFR targeting (*p <0.05). Similarly, the PD-L1 concentration of 
MDA-MB-231 cells grown on the soft substrate was significantly lower than those grown on 
the stiff substrate (*p<0.05). The values of 1620±29 pg/ml, 1500±49 pg/ml, and 1000±66 












above-mentioned results suggest that PD-L1 expression could be mediated by chemical and 
mechanical tumor microenvironmental cues. 
To further confirm these results, the PD-L1 staining of spread aggregates was accompanied 
with measuring of PD-L1 concentration using ELISA (figure 7B). Among the five study 
groups of MCF7, we found the highest PD-L1 level in the non-treated group. In line with the 
data assessed by the immunofluorescent microscopy, MCF7 cells appeared as PD-L1 positive 
after MCA formation. Furthermore, the PD-L1 concentration of spread MCAs of MCF7 
reached 214±28 pg/ml, 153±19 pg/ml and 151±24 pg/ml in stiff, semi-soft, and soft groups, 
respectively. In contrast, MDA-MB-231 cells did not exhibit a significant change in the PD-
L1 concentration after MCA formation. In agreement with the previous results, spread 
aggregates of MDA-MB-231 cells exhibited noticeable PD-L1 expression mediated by EGFR 
blocking and substrate stiffening, so that Cetuximab treatment caused a decrease in PD-L1 
expression in these cells.  
3.5 The TCGA data analysis 
The genomic alteration analysis shows that the basal subtype of breast cancer exhibits the 
highest expression and amplification of EGFR, PD-L1 (CD274) and PROM-1 compared to 
other subtypes (Figure 8A). Furthermore, positive correlation and co-expression between PD-
L1 with EGFR, CD44 and epithelial to mesenchymal transition-related transcription factors 
(EMT-TFs) SNAI1, ZEB1 and TWIST1 were observed (Figure 8B). In line with these 
results, the protein-protein interaction analysis illustrated a direct interaction between PD-L1 













It is well established that the expression of PD-L1 plays an important role in cancer cell-
mediated immune response. Expression of PD-L1 has been found in 5–40% tumor cells, 
helping tumor cells to escape from the immune elimination [39]. PD-L1 is one of the key 
molecular pathways used by tumor cells to engage T cell immune checkpoints. PD-L1 
expressed on the surface of tumor cells binds to PD1, which is expressed by activated T cells, 
leading to bypassing immune checkpoints to evade immune recognition and protects tumor 
cells from T cell-mediated killing [40]. 
The cellular expression of PD-L1 could be affected by different chemical and mechanical 
factors of tumor microenvironment. Hence, identifying cellular and molecular mechanisms 
driving PD-L1 expression is crucial for the successful prediction of response to the PD-L1 
targeted therapy. In this study, the effect of EGFR signaling and substrate stiffness, two 
important tumor microenvironmental factors on PD-L1 expression of breast cancer cells, was 
investigated. Further, we evaluated whether MCA formation of breast cancer cells could 
contribute to enhancing PD-L1 expression. It has been demonstrated that different cancer cell 
types express different levels of PD-L1 that could be associated with their invasive potential 
[41]. Kim et al. indicated that metastatic lung cancers express more PD-L1 as compared to 
the primary tumor [42]. A similar result was observed for breast cancer cells [38, 41]. Our 
finding also confirmed high PD-L1 expression of invasive MDA-MB-231 cells, while non-
invasive MCF7 cells display a modest level of PD-L1 (*p<0.05).  
Moreover, PD-L1 level of MDA-MB-231 cells is modulated by EGFR signaling and 
substrate stiffening. There are several studies which evaluated the effect of substrate stiffness 
on the cellular behavior of cancer cells [43, 44]. They cultured different types of cells usually 












[36, 37, 45]. In this study, choosing three different ratios of elastomer to curing agents for 
PDMS substrates resulted in the stiffness of 5KPa to 1MPa while the curing agent ratio was 
enough to achieve a complete polymerization process of PDMS. These range of stiffness is 
consistent with previously published data [46] and close to tumor stromal microenvironment 
[37, 47]. They reached the conclusion that cancer cells respond to the substrate rigidity by 
changing protein expression, proliferation, migration and differentiation ability. Most 
recently, Myazawa et al. probed the effect of substrate stiffness on the PD-L1 expression of 
lung cancer cells [48].  They demonstrated that substrate stiffening enhanced the PD-L1 level 
via actin-dependent mechanisms. Here, we investigated such a relationship by culturing 
breast cancer cells on stiff, semi-soft and soft PDMS substrates and demonstrated the relation 
between substrate stiffness and PD-L1 expression.  
The association between EGFR and PD-L1 signaling pathways plays an important role in 
cancer targeted therapy and is gaining much more interest in recent years. Several studies 
evidenced a positive correlation between EGFR activity and PD-L1 expression [49, 50].  
MDA-MB-231 cells have been shown to express a high level of EGFR, which render them as 
a suitable target for anti-EGFR treatment [51, 52]. EGFR is involved in the modulation of 
PD-L1 expression through AKT and STAT3 downstream signaling pathways [53, 54]. 
Regarding the correlation between these two important signaling pathways, much more 
attention has been paid for a combined targeting of EGFR and PD-L1 in recent years [55].  
Our results indicated that EGFR-positive MDA-MB-231 cells expressed a high level of PD-
L1, while EGFR-negative MCF7 cells did not show a significant level of PD-L1, which is in 
good agreement with previously published papers [38, 41]. Moreover, Cetuximab treatment 
of MDA-MB-231 cells was accompanied with a noticeable reduction of PD-L1, which 












In line with these results, few preclinical studies on patients with advanced lung 
adenocarcinoma highlighted that acquired resistance to EGFR-TKIs can amplify the 
expression of PD-L1 and enhance immune escape in EGFR mutant lung adenocarcinoma in 
which targeting PD-L1 restored sensitivity of tumor cells to lymphocytes [56]. Interestingly, 
in a clinical study conducted by Lee and colleagues in EGFR-mutated lung adenocarcinomas 
patients treated with first-line EGFR-TKIs, the high tumor proportion score of PD-L1 
negatively associated with the treatment response rate and the patient outcome, compared to 
EGFR-TKI sensitive tumor cells [57]. These results not only highlight a positive association 
between EGFR and PD-L1 expression, but also indicate the potential application of PDL-1 
expression as a prognostic biomarker for patients with EGFR mutation.  
There are various factors that could be influential in PD-L1 expression. It has been shown 
that PD-L1 contributes to cancer stemness, EMT and tumor invasion, albeit not focusing on 
EMT and stemness [50, 58, 59]. Noman et al. demonstrated that PD-L1 is upregulated 
through EMT activation of breast cancer cells by involving ZEB-1 and miR-200 [60]. Here, 
by analyzing data of invasive breast cancers from The Cancer Genome Atlas (TCGA) and 
protein-protein interaction, we illustrated a possible correlation between PD-L1 with EGFR, 
stemness-related genes, and EMT-TFs (Figure 8). In line with these results, Malta et al. 
reported a positive association between immune microenvironment content, PD-L1 levels and 
stemness features in breast cancer [59]. Additionally, the high expression of PD-L1 in CD44
+
 
breast cancer cells and its role in maintaining stemness factors including OCT-4A, Nanog and 
BMI1 have been reported [58, 61].   
In this study, two approaches, substrate stiffness and EGFR targeting, were used to change 
the PD-L1 expression of breast cancer cells. It has been demonstrated that both approaches 
could activate EMT and alter stemness factors [62-64]. Abhold et al. reported a reduction of 












stemness markers by substrate stiffening [62]. Regarding these studies, it can be concluded 
that both EGFR signaling and substrate stiffening could modulate the PD-L1 expression 
through the mediation of EMT and stemness.  
Our results indicated the successful formation of breast MCAs in both cell lines among five 
study groups. However, noticeable differences were observed in the MCA formation ability 
of breast cancer cells in terms of MCA diameter and number. The effect of substrate stiffness 
on the various cellular behaviors has been investigated, while there is not any report 
addressing the effect of substrate stiffening on the MCA formation. For the first time, to our 
knowledge, we showed that cancer cells derived from the stiff substrate had a greater ability 
to form MCA. Furthermore, the MCA formation was influenced not only with the substrate 
stiffness but also with the EGFR activity. Cetuximab-treated MCF7 and MDA-MB-231 cells 
indicated a decrease of 23% and 50% respectively in the number of formed MCAs compared 
to non-treated cells, respectively. The average diameter of MCAs also decreased from the 
stiff to the soft substrate. Moreover, analyzing the number and diameter of breast cancer 
MCA revealed that their aggregate formation ability positively correlated with the PD-L1 
expression level.  
In this study, MCAs were formed to investigate how cancer aggregate formation could alter 
the PD-L1 expression of breast cancer cells. Overall, the assessment of PD-L1 level by 
immunostaining as well as ELISA indicated that firstly, MCAs derived from cells grown on 
the stiff substrate showed a higher level of PD-L1 among the three PDMS substrates, 
secondly, EGFR targeting decreased the PD-L1 level not only in the cancer cell monolayer 
but also in MCAs, and thirdly, the MCA formation considerably enhanced  PD-L1 expression 












Stemness markers could be affected by different mechanisms through spheroidogenesis of 
cancer cells [25]. Chen et al. reported that spheroid formation led to overexpression of 
stemness-related genes [65]. Moreover, it has been shown that formation of MCA could 
guide EMT shifting and collective cell invasion through Snail1, Vimentin, and E-cadherin 
gene expression alterations [66]. Furthermore, as discussed before, stemness markers and 
EMT process also correlate to PD-L1 expression. Our finding also demonstrated the 
association between MCA formation and PD-L1 expression. Taken together, our results 
suggest that the formation of MCAs could modulate the PD-L1 expression of MCF7 cells 
through the possible mediation of stemness markers and/or EMT factors. 
Molecular targeted therapy (e.g., EGFR and Her2 inhibitors) and immunotherapy (e.g., 
PD1/PD-L1 inhibitors) are two of the most important approaches in cancer treatment. Unlike 
molecular targeted therapy, the prediction of response to immunotherapy faces more 
challenges. Although PD-L1 expression is widely used as a predictive biomarker to 
immunotherapy, to date, many immunotherapy treatments have demonstrated a low efficacy 
in most patients [67]. Our results indicate that even for PD-L1-negative cancer cells such as 
MCF7, PD-L1 expression could be altered by different cellular and molecular mechanisms, 
and in such a situation different therapeutic approaches should be considered. Therefore, 
successful prediction of response to immunotherapy, specifically PD-L1 targeting, requires 
much more experimentation in 2D and 3D microenvironments, under various chemical and 
mechanical conditions. Moreover, the correlation between EGFR and PD-L1 supports the 
approach of combination therapy as a more effective strategy to modulate cancer cell- 













In summary, we showed that PD-L1 expression, an important biomarker of immunotherapy, 
is modulated by both substrate stiffness and EGFR activity. Further, we demonstrated that the 
PD-L1 expression level is associated with the formation of cellular aggregates. So, even for 
those cancer cells with a low level of PD-L1, the possible changes in the cancer cell- immune 
cell interaction should be considered. Overall, to achieve a successful prediction of response 
to immunotherapy, different influential chemical and mechanical factors should be examined. 
The evidence from this study has gone some way toward enhancing our understanding of 
factors which modulate the PD-L1 expression. Our findings suggest two possible 
relationships, firstly between the MCA formation and PD-L1 expression, and secondly, 
between PD-L1 expression and stemness/EMT markers which are involved in cancer 
progression. Further experiments will be required to determine which mechanisms underly 
the regulation of PD-L1 expression during the EMT and acquired stemness features.  
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Figure. 1 Schematic illustration of the workflow. Breast cancer cells were cultured among 
chemical and mechanical study groups and assessed for PD-L1 expression before and after 
formation of multicellular aggregates.  
Figure. 2 Regulation of PD-L1 expression by EGFR signaling and substrate stiffening. 
Representative immunofluorescent images of (A) MCF7 and (B) MDA-MB-231 cells 
cultured on non-treated, EGFR treated, stiff, semi-soft, and soft groups for 24 hours, stained 
for PD-L1 (red) and nuclei (blue). Images were obtained using an inverted fluorescent 
microscope. Scale bar denotes 50 µm and experiments were repeated three times. 
Figure. 3 Schematic of the SpheroFilm utilized to generate multicellular cancer 
aggregates (MCAs) and representative images of the MCA formation of breast cancer 
cells. Scale bar is 100 µm. (I) Side view of the SpheroFilm contains 361 microwells with a 
diameter of 300 µm, and depth of 300 µm (II) Breast cancer cells were seeded into the 
microwells (day 0) among five study groups of non-treated, CTX-treated, stiff, semi-soft, and 
soft (III) The cancer cells grouped together to form cell aggregates after 1 day (IV) Cell 
aggregates formed dense 3D spherical structures after 2 days (V) MCAs were isolated from 
SpheroFilm and strained with a 100µm pore filter. 
Figure. 4 MCA characterization. (A) live and dead assay reveals excellent viability of 3D 
MCAs of MCF7 and MDA-MB-231 cells among five chemical and mechanical treated 
groups. The live cells were stained with Calcein AM (Green), and the dead cells were stained 
with PI (Red), as described in materials and methods. Arrows show some of dead cells. The 
images were obtained by fluorescent microscopy with a scale bar of 100 µm. (B and C) 
Number and diameter of MCAs with (B) MCF7 and (C) MDA-MB-231 cells. The number of 
MCAs has been represented as the mean ± SD of three independent experiments.  The mean 
diameter of MCAs has been represented as the mean ± SD of at least 40 MCAs in each 
group.  
Figure. 5 Role of the MCA formation in the PD-L1 expression of breast cancer cells. 
Representative bright field and immunofluorescence images of (A) MCF7 and (B) MDA-
MB-231 MCAs in five study groups of non-treated, CTX-treated, stiff, semi-soft, and soft, 
stained for PD-L1 (red) and nuclei (blue). Images were obtained using a fluorescent 
microscope, and scale bar denotes 50 µm and experiments were repeated three times. 
Figure. 6 PD-L1 expression of spread MCAs of breast cancer cells as a function of 
EGFR activity and substrate stiffness. Representative bright field and immunofluorescence 
images of (A) MCF7 and (B) MDA-MB-231 MCAs in five study groups which were stained 
for PD-L1 (red) and nuclei (blue). Images were obtained using a fluorescent microscope. 
Scale bar represents 100 µm and experiments were repeated three times. (C) Mean 
fluorescent intensity was analyzed using ImageJ. The values are mean ± SD of three 
independent experiments. *significantly different between the groups (p< 0.05) and ** (p< 
0.005). 
Figure. 7 Comparison of protein concentration of PD-L1 in the chemical and 
mechanical groups, before and after formation of MCAs. The PD-L1 concentration of two 
breast cancer cell lines, MCF7 and MDA-MB-231 cells was measured by ELISA among five 












and (B) after MCA formation. The values are mean ± SD of three independent experiments 
with duplicate measurements for each. * significantly different between the groups (p< 0.05) 
and ** (p< 0.005). 
Figure. 8 Genomic and protein-protein interaction analysis of PD-L1. (A) The TCGA 
Pan-Breast Cancer Atlas genomic analysis. The oncoprint data shows amplification and up-
regulation of PD-L1, EGFR, and PROM-1 in Basal subtype of breast cancer compared to 
other subtypes. (B) Co-expression and correlation analysis of PD-L1 expression with EGFR, 
CD44, and core EMT-TFs (C) protein-protein network interaction between PD-L1, EGFR 



















 Matrix stiffness regulates PD-L1 expression in breast cancer cells 
 PD-L1 expression level is strongly influenced by EGFR signaling 
 Formation of multicellular aggregates induces PD-L1 expression in breast cancer cells 
 There is a positive correlation between PD-L1 with EGFR, EMT factors and stemness 
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